1592-62-7Relevant articles and documents
Catalytic Enantioselective Synthesis of Tetrahydocarbazoles and Exocyclic Pictet-Spengler-Type Reactions
Hansen, Casper L.,Ohm, Ragnhild G.,Olsen, Lasse B.,Ascic, Erhad,Tanner, David,Nielsen, Thomas E.
, p. 5990 - 5993 (2016)
A synthetic strategy for the synthesis of chiral tetrahydrocarbazoles (THCAs) has been developed. The strategy relies on two types of 6-exo-trig cyclization of 3-substituted indole substrates. Enantioselective domino Friedel-Crafts-type reactions leading to THCAs can be catalyzed by chiral phosphoric acid derivatives (with up to >99% ee), and the first examples of exocyclic Pictet-Spengler reactions to form THCAs are reported.
Enantioselective Synthesis of 1- and 4-Hydroxytetrahydrocarbazoles through Asymmetric Transfer Hydrogenation
Dilek, ?mer,Patir, Süleyman,Ertürk, Erkan
supporting information, p. 69 - 72 (2019/01/04)
Several 1- and 4-hydroxytetrahydrocarbazoles were prepared in high yields (up to 99%) and excellent enantiomeric excesses (up to >99% ee) from the corresponding 1- and 4-oxotetrahydrocarbazoles through asymmetric transfer hydrogenation by using the commercially available Noyori-Ikariya ruthenium catalyst. The immediate use of the freshly prepared catalyst and the use of a HCO 2 H-DABCO (11:6) mixture as the hydrogen source are crucial for achieving high activity and enantioselectivity. In this way, a tetrahydrocarbazole heterocycle fused to a lactone moiety was synthesized in 45% yield and 97% ee.
Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists
Di Fabio, Romano,Giovannini, Riccardo,Bertani, Barbara,Borriello, Manuela,Bozzoli, Andrea,Donati, Daniele,Falchi, Alessandro,Ghirlanda, Damiano,Leslie, Colin P.,Pecunioso, Angelo,Rumboldt, Giovanna,Spada, Simone
, p. 1749 - 1752 (2007/10/03)
The SAR of a new series of tetrahydrocarbazole derivatives is described: the appropriate decoration of this template led to the identification of a new class of NPY-1 antagonists showing good in vitro potency and a promising in vivo pharmacokinetic profil